Anti-Rheumatic Drugs - Pakistan

Pakistan

The Anti-Rheumatic Drugs market in Pakistan is expected to witness a significant increase in revenue, reaching a projected value of US$25.88m by 2024.
This growth is anticipated to continue with an annual growth rate of 0.92% from 2024 to 2029, resulting in a market volume of US$27.09m by the end of 2029.
When compared to other countries globally, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market, amounting to US$34,700.00m in 2024.
Pakistan's market for anti-rheumatic drugs is growing steadily due to an aging population and increasing prevalence of rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Pakistan has been growing at a steady pace in recent years.

Customer preferences: The primary customer base for Anti-Rheumatic Drugs in Pakistan is the elderly population, who are more likely to suffer from rheumatic diseases such as osteoarthritis. The younger population also contributes to the demand for these drugs due to the increasing prevalence of autoimmune diseases.

Trends in the market: The Anti-Rheumatic Drugs market in Pakistan has been witnessing a shift towards biologics, which are more effective in treating rheumatic diseases. Additionally, there has been an increase in the number of generic drugs available in the market, which has led to price competition and made these drugs more accessible to a larger population.

Local special circumstances: One of the major challenges faced by the Anti-Rheumatic Drugs market in Pakistan is the lack of awareness about rheumatic diseases among the general population. This has resulted in a delay in diagnosis and treatment, which can lead to more severe health complications. Furthermore, the limited healthcare infrastructure and the high cost of treatment have also hindered the growth of the market.

Underlying macroeconomic factors: The growing population and increasing life expectancy in Pakistan have contributed to the demand for Anti-Rheumatic Drugs. Additionally, the government's focus on improving healthcare infrastructure and increasing healthcare spending has created opportunities for growth in the market. However, the political instability and economic challenges faced by the country have also had a negative impact on the market, leading to fluctuations in demand and supply.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.